Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

CytoDyn Inventory 2010-2024 | CYDY

CytoDyn inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  
CytoDyn Annual Inventory
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $19
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
CytoDyn Quarterly Inventory
(Millions of US $)
2024-08-31
2024-05-31
2024-02-29
2023-11-30
2023-08-31
2023-05-31
2023-02-28
2022-11-30
2022-08-31
2022-05-31
2022-02-28 $83
2021-11-30 $89
2021-08-31 $92
2021-05-31
2021-02-28 $94
2020-11-30 $99
2020-08-31 $58
2020-05-31 $19
2020-02-29 $16
2019-11-30
2019-08-31
2019-05-31
2019-02-28
2018-11-30
2018-08-31
2018-05-31
2018-02-28
2017-11-30
2017-08-31
2017-05-31
2017-02-28
2016-11-30
2016-08-31
2016-05-31
2016-02-29
2015-11-30
2015-08-31
2015-05-31
2015-02-28
2014-11-30
2014-08-31
2014-05-31
2014-02-28
2013-11-30
2013-08-31
2013-05-31
2013-02-28
2012-11-30
2012-08-31
2012-05-31
2012-02-29
2011-11-30
2011-08-31
2011-05-31
2011-02-28
2010-11-30
2010-08-31
2010-05-31
2010-02-28
2009-11-30
2009-08-31
2009-05-31
2009-02-28
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.144B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.725B 30.68
Takeda Pharmaceutical (TAK) Japan $42.414B 8.83
Sandoz Group AG (SDZNY) Switzerland $19.283B 0.00
Merck (MKKGY) Germany $18.792B 16.83
Astellas Pharma (ALPMY) Japan $18.332B 16.88
United Therapeutics (UTHR) United States $16.401B 16.13
Summit Therapeutics (SMMT) United States $13.584B 0.00
Neurocrine Biosciences (NBIX) United States $12.656B 33.51
Shionogi (SGIOY) Japan $11.814B 11.32
Catalent (CTLT) United States $10.829B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.563B 7.40
Madrigal Pharmaceuticals (MDGL) United States $7.181B 0.00
Orion OYJ (ORINY) Finland $6.653B 18.71
Corcept Therapeutics (CORT) United States $5.859B 44.38
Ionis Pharmaceuticals (IONS) United States $5.359B 0.00
Crinetics Pharmaceuticals (CRNX) United States $5.289B 0.00
PTC Therapeutics (PTCT) United States $3.308B 0.00
Dyne Therapeutics (DYN) United States $3.026B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.578B 15.41
Catalyst Pharmaceuticals (CPRX) United States $2.519B 11.42
Soleno Therapeutics (SLNO) United States $2.356B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.272B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.061B 0.00
Evotec AG (EVO) Germany $1.896B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.859B 0.00
Xencor (XNCR) United States $1.687B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.648B 0.00
Harrow (HROW) United States $1.563B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.551B 0.00
Cassava Sciences (SAVA) United States $1.548B 0.00
Indivior (INDV) United States $1.484B 6.04
Guardian Pharmacy Services (GRDN) United States $1.397B 0.00
Ocular Therapeutix (OCUL) United States $1.339B 0.00
ARS Pharmaceuticals (SPRY) United States $1.300B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.256B 0.00
Enliven Therapeutics (ELVN) United States $1.242B 0.00
Ardelyx (ARDX) United States $1.213B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.124B 0.00
Collegium Pharmaceutical (COLL) United States $0.981B 5.35
Bioventus (BVS) United States $0.934B 29.51
Cronos Group (CRON) Canada $0.784B 0.00
Relay Therapeutics (RLAY) United States $0.777B 0.00
USANA Health Sciences (USNA) United States $0.750B 13.91
Oruka Therapeutics (ORKA) United States $0.717B 0.00
Elite Pharmaceuticals (ELTP) United States $0.660B 0.00
Exscientia (EXAI) United Kingdom $0.633B 0.00
Altimmune (ALT) United States $0.598B 0.00
Tourmaline Bio (TRML) United States $0.583B 0.00
Savara (SVRA) United States $0.556B 0.00
OmniAb (OABI) United States $0.544B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.534B 0.00
Organogenesis (ORGO) United States $0.533B 0.00
ProKidney (PROK) United States $0.507B 0.00
Zevra Therapeutics (ZVRA) United States $0.487B 0.00
Esperion Therapeutics (ESPR) United States $0.487B 0.00
Korro Bio (KRRO) United States $0.474B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.473B 0.00
Xeris Biopharma Holdings (XERS) United States $0.453B 0.00
Siga Technologies (SIGA) United States $0.448B 5.22
Rigel Pharmaceuticals (RIGL) United States $0.441B 178.86
Aquestive Therapeutics (AQST) United States $0.411B 0.00
KalVista Pharmaceuticals (KALV) United States $0.403B 0.00
Akebia Therapeutics (AKBA) United States $0.397B 0.00
Larimar Therapeutics (LRMR) United States $0.391B 0.00
Verve Therapeutics (VERV) United States $0.389B 0.00
4D Molecular Therapeutics (FDMT) United States $0.369B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.356B 0.00
Avita Medical (RCEL) United States $0.337B 0.00
Aclaris Therapeutics (ACRS) United States $0.309B 0.00
Sage Therapeutics (SAGE) United States $0.297B 0.00
Nature's Sunshine Products (NATR) United States $0.289B 17.21
Aldeyra Therapeutics (ALDX) United States $0.286B 0.00
Lyell Immunopharma (LYEL) United States $0.256B 0.00
Silence Therapeutics (SLN) United Kingdom $0.230B 0.00
Lexeo Therapeutics (LXEO) United States $0.205B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.204B 0.00
Acrivon Therapeutics (ACRV) United States $0.201B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.197B 0.00
Nektar Therapeutics (NKTR) United States $0.186B 0.00
Profound Medical (PROF) Canada $0.185B 0.00
MediWound (MDWD) Israel $0.181B 0.00
Nanobiotix S.A (NBTX) France $0.181B 0.00
Galectin Therapeutics (GALT) United States $0.171B 0.00
Heron Therapeutics (HRTX) United States $0.161B 0.00
Achieve Life Sciences (ACHV) Canada $0.149B 0.00
VAXART, INC (VXRT) United States $0.136B 0.00
Inhibikase Therapeutics (IKT) United States $0.135B 0.00
Telomir Pharmaceuticals (TELO) United States $0.132B 0.00
Cardiol Therapeutics (CRDL) Canada $0.129B 0.00
Pyxis Oncology (PYXS) United States $0.125B 0.00
Context Therapeutics (CNTX) United States $0.113B 0.00
Journey Medical (DERM) United States $0.109B 0.00
Century Therapeutics (IPSC) United States $0.105B 0.00
Innate Pharma SA (IPHYF) France $0.103B 0.00
Avalo Therapeutics (AVTX) United States $0.100B 0.00
Fractyl Health (GUTS) United States $0.099B 0.00
Karyopharm Therapeutics (KPTI) United States $0.097B 0.00
Assertio Holdings (ASRT) United States $0.092B 24.14
Regulus Therapeutics (RGLS) United States $0.092B 0.00
Arch Biopartners (ACHFF) Canada $0.090B 0.00
Inotiv (NOTV) United States $0.089B 0.00
PMV Pharmaceuticals (PMVP) United States $0.083B 0.00
Relmada Therapeutics (RLMD) United States $0.083B 0.00
CASI Pharmaceuticals (CASI) China $0.081B 0.00
Vivani Medical (VANI) United States $0.079B 0.00
ESSA Pharma (EPIX) Canada $0.078B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 0.00
Scienture Holdings (SCNX) United States $0.069B 0.00
Metagenomi (MGX) United States $0.068B 0.00
AlloVir (ALVR) United States $0.066B 0.00
ElectroCore (ECOR) United States $0.065B 0.00
OptiNose (OPTN) United States $0.060B 0.00
Champions Oncology (CSBR) United States $0.058B 0.00
Mural Oncology (MURA) Ireland $0.057B 0.00
BioVie (BIVI) United States $0.055B 0.00
Nutriband (NTRB) United States $0.055B 0.00
Unicycive Therapeutics (UNCY) United States $0.055B 0.00
Prelude Therapeutics (PRLD) United States $0.053B 0.00
Rafael Holdings (RFL) United States $0.050B 0.00
Iterum Therapeutics (ITRM) Ireland $0.049B 0.00
Protara Therapeutics (TARA) United States $0.047B 0.00
SCYNEXIS (SCYX) United States $0.045B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.045B 0.00
Gain Therapeutics (GANX) United States $0.043B 0.00
VYNE Therapeutics (VYNE) United States $0.043B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Tempest Therapeutics (TPST) United States $0.039B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.038B 0.00
CERo Therapeutics Holdings (CERO) United States $0.037B 0.00
Carisma Therapeutics (CARM) United States $0.035B 0.00
Incannex Healthcare (IXHL) Australia $0.035B 0.00
Surrozen (SRZN) United States $0.030B 0.00
Citius Pharmaceuticals (CTXR) United States $0.030B 0.00
DURECT (DRRX) United States $0.027B 0.00
Lipocine (LPCN) United States $0.027B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.026B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
BioLineRx (BLRX) Israel $0.026B 0.00
GlycoMimetics (GLYC) United States $0.021B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
ProPhase Labs (PRPH) United States $0.019B 0.00
Enlivex Therapeutics (ENLV) Israel $0.018B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
TherapeuticsMD (TXMD) United States $0.015B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.015B 0.00
NRx Pharmaceuticals (NRXP) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Traws Pharma (TRAW) United States $0.014B 0.00
Nuvilex (PMCB) United States $0.013B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.013B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
Talphera (TLPH) United States $0.012B 0.00
Jaguar Animal Health (JAGX) United States $0.012B 0.00
Conduit Pharmaceuticals (CDT) United States $0.011B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Redhill Biopharma (RDHL) Israel $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Klotho Neurosciences (KLTO) United States $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
Viracta Therapeutics (VIRX) United States $0.006B 0.00
Biomerica (BMRA) United States $0.005B 0.00
Aditxt (ADTX) United States $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.11
Aptorum Group (APM) United Kingdom $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Bio-Path Holdings (BPTH) United States $0.003B 0.00
Oncternal Therapeutics (ONCT) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Molecular Templates (MTEM) United States $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 2.13
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 38.47